Biosimilar Testing and Development Services Market By Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Biosimilar Testing and Development Services Market," The biosimilar testing and development services market was valued at $2.5 billion in 2022, and is estimated to reach $7.8 billion by 2032, growing at a CAGR of 12.1% from 2023 to 2032.

Biosimilar Testing and Development Services Market - IMG1

In addition, biologics drugs, which are highly effective in treating various chronic and life-threatening diseases, often come with high price tags, making them inaccessible to a large segment of the population. However, biosimilars, which are comparable versions of reference biologics, present a promising solution to this problem. Biosimilar drugs undergo a rigorous development process to demonstrate dissimilarity to the reference product in terms of quality, safety, and efficacy. Once approved, biosimilars can offer significant cost savings as compared to the original biologic drugs. According to Association for Accessible Medicines (U.S.), in 2021, biosimilars generated $7 billion in savings for patients and the healthcare system. This cost advantage has the potential to drive healthcare expenditure, making essential treatments more accessible to patients while also reducing the financial burden on healthcare systems. Rise in demand for biosimilar product results in demand for services that facilitate the testing and development of biosimilars.

However, stringent regulatory requirements might act as a restraint for the growth of the market. However, patent expiration of biological drugs is expected to serve as a growth opportunity in the market.

The biosimilar testing and development services market is segmented on the basis of type and end user, and region. By type, the market is categorized into pharmacokinetics, immunogenicity, and others. The others include, ligand binding assay, biomarker, and stability testing. By end user, the market is categorized into pharmaceutical and biopharmaceutical companies, contract research organizations, and others. Others include contract development and manufacturing organization, independent lab, and regulatory bodies. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global biosimilar testing and development services market are Charles River Laboratories, Element Materials Technology, Intertek Group plc, Pacific biolabs, Inc, Profacgen Technologies Inc, Sartorius AG, SGS, BioPharmaSpec Ltd., Veeda Clinical Research Pvt. Ltd, and Eurofins Scientific SE.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimilar testing and development services market analysis from 2022 to 2032 to identify the prevailing biosimilar testing and development services market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biosimilar testing and development services market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biosimilar testing and development services market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data

Key Market Segments

By Type

Pharmacokinetics Assay
Immunogenicity Testing
Others

By End User

Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Sartorius AG
Pacific Biolabs, Inc.
BioPharmaSpec Ltd.
Charles River Laboratories
Intertek Group plc
SGS
Veeda Clinical Research Pvt. Ltd.
Eurofins Scientific SE
Profacgen Technologies Inc.
Element Materials Technology

Product Code: A03627

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Surge in need of biosimilar testing facilities.
  - 3.4.1.2. Rise in outsourcing of preclinical, clinical, and laboratory testing services by pharma and biotech companies
- 3.4.2. Restraints
  - 3.4.2.1. Stringent regulatory requirements.
- 3.4.3. Opportunities
  - 3.4.3.1. Patent expirations of biologic drugs.

CHAPTER 4: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Pharmacokinetics Assay
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Immunogenicity Testing
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Pharmaceutical and Biopharmaceutical Companies
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Contract Research Organizations
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Type
- 6.2.3. Market size and forecast, by End User
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Type
  - 6.2.4.1.2. Market size and forecast, by End User
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Type
  - 6.2.4.2.2. Market size and forecast, by End User
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Type
  - 6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Type
- 6.3.3. Market size and forecast, by End User
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Type
  - 6.3.4.1.2. Market size and forecast, by End User
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Type
  - 6.3.4.2.2. Market size and forecast, by End User
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Type
  - 6.3.4.3.2. Market size and forecast, by End User
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Market size and forecast, by Type
  - 6.3.4.4.2. Market size and forecast, by End User
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Market size and forecast, by Type
  - 6.3.4.5.2. Market size and forecast, by End User
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Market size and forecast, by Type
  - 6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Type
- 6.4.3. Market size and forecast, by End User
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Market size and forecast, by Type
  - 6.4.4.1.2. Market size and forecast, by End User
  - 6.4.4.2. China
  - 6.4.4.2.1. Market size and forecast, by Type
  - 6.4.4.2.2. Market size and forecast, by End User
  - 6.4.4.3. India
  - 6.4.4.3.1. Market size and forecast, by Type
  - 6.4.4.3.2. Market size and forecast, by End User
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Market size and forecast, by Type
  - 6.4.4.4.2. Market size and forecast, by End User
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Type
  - 6.4.4.5.2. Market size and forecast, by End User
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Type
  - 6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Type
- 6.5.3. Market size and forecast, by End User
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Type
  - 6.5.4.1.2. Market size and forecast, by End User
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Market size and forecast, by Type
  - 6.5.4.2.2. Market size and forecast, by End User
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Market size and forecast, by Type
  - 6.5.4.3.2. Market size and forecast, by End User
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Market size and forecast, by Type
  - 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. BioPharmaSpec Ltd.
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
8.2. Charles River Laboratories
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
8.3. Element Materials Technology
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
8.4. Eurofins Scientific SE
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
8.5. Intertek Group plc
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
8.6. Pacific Biolabs, Inc.
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Key strategic moves and developments
8.7. Profacgen Technologies Inc.
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
8.8. Sartorius AG
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. SGS
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. Veeda Clinical Research Pvt. Ltd.
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio